Is TNYA or ALLO more profitable?

Allogene Therapeutics' return on equity of -56.45% beat Tenaya Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tenaya Therapeutics N/A -80.56% -65.21% Allogene Therapeutics N/A -56.45% -40.36%

Does the media favor TNYA or ALLO?

In the previous week, Tenaya Therapeutics had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 5 mentions for Tenaya Therapeutics and 4 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.12 beat Tenaya Therapeutics' score of 0.41 indicating that Allogene Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenaya Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Allogene Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, SLDB or TNYA?

Solid Biosciences is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Solid Biosciences N/A N/A -$174.32M -$1.95 N/A Tenaya Therapeutics N/A N/A -$90.60M -$0.47 N/A

Is SLDB or TNYA more profitable?

Solid Biosciences' return on equity of -73.42% beat Tenaya Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Solid Biosciences N/A -73.42% -61.13% Tenaya Therapeutics N/A -80.56% -65.21%

Does the media prefer SLDB or TNYA?

In the previous week, Solid Biosciences had 10 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 15 mentions for Solid Biosciences and 5 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.41 beat Solid Biosciences' score of 0.24 indicating that Tenaya Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Solid Biosciences 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Tenaya Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings & valuation, TNYA or REPL?

Replimune Group is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tenaya Therapeutics N/A N/A -$90.60M -$0.47 N/A Replimune Group N/A N/A -$247.30M -$3.44 N/A

Is TNYA or REPL more profitable?

Tenaya Therapeutics' return on equity of -80.56% beat Replimune Group's return on equity. Company Net Margins Return on Equity Return on Assets Tenaya Therapeutics N/A -80.56% -65.21% Replimune Group N/A -102.69% -72.22%

Does the media favor TNYA or REPL?

In the previous week, Tenaya Therapeutics had 2 more articles in the media than Replimune Group. MarketBeat recorded 5 mentions for Tenaya Therapeutics and 3 mentions for Replimune Group. Replimune Group's average media sentiment score of 0.44 beat Tenaya Therapeutics' score of 0.41 indicating that Replimune Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tenaya Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Replimune Group 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, ANRO or TNYA?

Alto Neuroscience is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alto Neuroscience N/A N/A -$63.24M -$2.42 N/A Tenaya Therapeutics N/A N/A -$90.60M -$0.47 N/A

Is ANRO or TNYA more profitable?

Alto Neuroscience's return on equity of -47.22% beat Tenaya Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alto Neuroscience N/A -47.22% -38.81% Tenaya Therapeutics N/A -80.56% -65.21%

Does the media favor ZVRA or TNYA?

In the previous week, Zevra Therapeutics had 9 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 14 mentions for Zevra Therapeutics and 5 mentions for Tenaya Therapeutics. Zevra Therapeutics' average media sentiment score of 0.47 beat Tenaya Therapeutics' score of 0.41 indicating that Zevra Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Tenaya Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Tenaya Therapeutics (TNYA) Competitors

$0.70 -0.01 (-1.41%)

Closing price 04:00 PM Eastern

Extended Trading

$0.70 0.00 (-0.29%)

As of 07:56 PM Eastern

Compare

TNYA vs. ALLO, SLDB, REPL, ANRO, and ZVRA

Should you buy Tenaya Therapeutics stock or one of its competitors? MarketBeat compares Tenaya Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Tenaya Therapeutics include Allogene Therapeutics (ALLO), Solid Biosciences (SLDB), Replimune Group (REPL), Alto Neuroscience (ANRO), and Zevra Therapeutics (ZVRA). These companies are all part of the "pharmaceutical products" industry.

How does Tenaya Therapeutics compare to Allogene Therapeutics?

Tenaya Therapeutics (NASDAQ:TNYA) and Allogene Therapeutics (NASDAQ:ALLO) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, analyst recommendations, institutional ownership, media sentiment, valuation, dividends, earnings and profitability.

Tenaya Therapeutics presently has a consensus price target of $4.00, suggesting a potential upside of 471.43%. Allogene Therapeutics has a consensus price target of $8.52, suggesting a potential upside of 378.78%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Tenaya Therapeutics is more favorable than Allogene Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69

In the previous week, Tenaya Therapeutics had 1 more articles in the media than Allogene Therapeutics. MarketBeat recorded 5 mentions for Tenaya Therapeutics and 4 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.12 beat Tenaya Therapeutics' score of 0.41 indicating that Allogene Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenaya Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allogene Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 83.6% of Allogene Therapeutics shares are held by institutional investors. 2.5% of Tenaya Therapeutics shares are held by insiders. Comparatively, 13.2% of Allogene Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Tenaya Therapeutics has a beta of 2.82, meaning that its stock price is 182% more volatile than the broader market. Comparatively, Allogene Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market.

Tenaya Therapeutics has higher earnings, but lower revenue than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.47	N/A
Allogene Therapeutics	$20K	30,718.35	-$190.89M	-$0.77	N/A

Allogene Therapeutics' return on equity of -56.45% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-80.56%	-65.21%
Allogene Therapeutics	N/A	-56.45%	-40.36%

Summary

Tenaya Therapeutics beats Allogene Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Solid Biosciences?

Solid Biosciences (NASDAQ:SLDB) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations, dividends and media sentiment.

In the previous week, Solid Biosciences had 10 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 15 mentions for Solid Biosciences and 5 mentions for Tenaya Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.41 beat Solid Biosciences' score of 0.24 indicating that Tenaya Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tenaya Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Solid Biosciences is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.47	N/A

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are held by institutional investors. 2.7% of Solid Biosciences shares are held by company insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Solid Biosciences presently has a consensus target price of $17.00, indicating a potential upside of 157.19%. Tenaya Therapeutics has a consensus target price of $4.00, indicating a potential upside of 471.43%. Given Tenaya Therapeutics' higher probable upside, analysts clearly believe Tenaya Therapeutics is more favorable than Solid Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Solid Biosciences' return on equity of -73.42% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-73.42%	-61.13%
Tenaya Therapeutics	N/A	-80.56%	-65.21%

Solid Biosciences has a beta of 2.43, suggesting that its share price is 143% more volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.82, suggesting that its share price is 182% more volatile than the broader market.

Summary

Tenaya Therapeutics beats Solid Biosciences on 7 of the 13 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Replimune Group?

Tenaya Therapeutics (NASDAQ:TNYA) and Replimune Group (NASDAQ:REPL) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, media sentiment, institutional ownership and valuation.

Tenaya Therapeutics' return on equity of -80.56% beat Replimune Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tenaya Therapeutics	N/A	-80.56%	-65.21%
Replimune Group	N/A	-102.69%	-72.22%

In the previous week, Tenaya Therapeutics had 2 more articles in the media than Replimune Group. MarketBeat recorded 5 mentions for Tenaya Therapeutics and 3 mentions for Replimune Group. Replimune Group's average media sentiment score of 0.44 beat Tenaya Therapeutics' score of 0.41 indicating that Replimune Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tenaya Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Replimune Group	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Tenaya Therapeutics has a beta of 2.82, suggesting that its stock price is 182% more volatile than the broader market. Comparatively, Replimune Group has a beta of 0.91, suggesting that its stock price is 9% less volatile than the broader market.

Replimune Group is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.47	N/A
Replimune Group	N/A	N/A	-$247.30M	-$3.44	N/A

90.5% of Tenaya Therapeutics shares are owned by institutional investors. Comparatively, 92.5% of Replimune Group shares are owned by institutional investors. 2.5% of Tenaya Therapeutics shares are owned by company insiders. Comparatively, 5.2% of Replimune Group shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Tenaya Therapeutics presently has a consensus price target of $4.00, indicating a potential upside of 471.43%. Replimune Group has a consensus price target of $4.88, indicating a potential downside of 42.44%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, research analysts plainly believe Tenaya Therapeutics is more favorable than Replimune Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Replimune Group	3 Sell rating(s)	7 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.70

Summary

Tenaya Therapeutics beats Replimune Group on 11 of the 14 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Alto Neuroscience?

Alto Neuroscience (NYSE:ANRO) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

In the previous week, Tenaya Therapeutics had 5 more articles in the media than Alto Neuroscience. MarketBeat recorded 5 mentions for Tenaya Therapeutics and 0 mentions for Alto Neuroscience. Tenaya Therapeutics' average media sentiment score of 0.41 beat Alto Neuroscience's score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Alto Neuroscience	Neutral
Tenaya Therapeutics	Neutral

Alto Neuroscience currently has a consensus target price of $35.25, indicating a potential upside of 79.35%. Tenaya Therapeutics has a consensus target price of $4.00, indicating a potential upside of 471.43%. Given Tenaya Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Tenaya Therapeutics is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.70
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Alto Neuroscience is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.47	N/A

90.5% of Tenaya Therapeutics shares are owned by institutional investors. 11.3% of Alto Neuroscience shares are owned by insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Alto Neuroscience has a beta of 1.22, meaning that its stock price is 22% more volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.82, meaning that its stock price is 182% more volatile than the broader market.

Alto Neuroscience's return on equity of -47.22% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-47.22%	-38.81%
Tenaya Therapeutics	N/A	-80.56%	-65.21%

Summary

Tenaya Therapeutics beats Alto Neuroscience on 9 of the 14 factors compared between the two stocks.

How does Tenaya Therapeutics compare to Zevra Therapeutics?

Zevra Therapeutics (NASDAQ:ZVRA) and Tenaya Therapeutics (NASDAQ:TNYA) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

Zevra Therapeutics has a net margin of 101.58% compared to Tenaya Therapeutics' net margin of 0.00%. Zevra Therapeutics' return on equity of 51.49% beat Tenaya Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	101.58%	51.49%	28.86%
Tenaya Therapeutics	N/A	-80.56%	-65.21%

Zevra Therapeutics has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market. Comparatively, Tenaya Therapeutics has a beta of 2.82, meaning that its stock price is 182% more volatile than the broader market.

35.0% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 90.5% of Tenaya Therapeutics shares are held by institutional investors. 2.4% of Zevra Therapeutics shares are held by company insiders. Comparatively, 2.5% of Tenaya Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Zevra Therapeutics has higher revenue and earnings than Tenaya Therapeutics. Tenaya Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zevra Therapeutics	$106.47M	7.50	$83.23M	$1.99	6.78
Tenaya Therapeutics	N/A	N/A	-$90.60M	-$0.47	N/A

In the previous week, Zevra Therapeutics had 9 more articles in the media than Tenaya Therapeutics. MarketBeat recorded 14 mentions for Zevra Therapeutics and 5 mentions for Tenaya Therapeutics. Zevra Therapeutics' average media sentiment score of 0.47 beat Tenaya Therapeutics' score of 0.41 indicating that Zevra Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zevra Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Tenaya Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Zevra Therapeutics currently has a consensus target price of $29.29, suggesting a potential upside of 116.93%. Tenaya Therapeutics has a consensus target price of $4.00, suggesting a potential upside of 471.43%. Given Tenaya Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Tenaya Therapeutics is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80
Tenaya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86

Summary

Zevra Therapeutics beats Tenaya Therapeutics on 10 of the 16 factors compared between the two stocks.

Get Tenaya Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TNYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TNYA vs. The Competition

Export

Metric	Tenaya Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$154.07M	$3.34B	$6.50B	$11.95B
Dividend Yield	N/A	2.31%	2.67%	5.61%
P/E Ratio	-1.49	18.83	24.65	23.63
Price / Sales	N/A	290.77	498.98	103.49
Price / Cash	N/A	120.20	43.05	54.72
Price / Book	1.23	8.00	10.43	6.70
Net Income	-$90.60M	$23.89M	$3.56B	$337.26M
7 Day Performance	-10.92%	-3.49%	-1.39%	-1.41%
1 Month Performance	-30.00%	1.03%	0.86%	1.15%
1 Year Performance	1.38%	34.39%	19.42%	22.61%

Tenaya Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TNYA Tenaya Therapeutics	3.008 of 5 stars	$0.70 -1.4%	$4.00 +471.4%	+3.6%	$154.07M	N/A	N/A	110
ALLO Allogene Therapeutics	2.9632 of 5 stars	$2.15 -0.9%	$8.52 +296.4%	+29.1%	$748.98M	$20K	N/A	310
SLDB Solid Biosciences	2.5562 of 5 stars	$7.19 -2.0%	$16.36 +127.6%	+42.2%	$722.62M	N/A	N/A	100
REPL Replimune Group	1.2962 of 5 stars	$9.00 +3.6%	$4.88 -45.8%	-9.2%	$717.56M	N/A	N/A	210	Upcoming Earnings Gap Down
ANRO Alto Neuroscience	1.8369 of 5 stars	$19.68 -2.0%	$35.25 +79.1%	+729.3%	$704.34M	N/A	N/A	N/A

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TNYA) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tenaya Therapeutics (TNYA) Competitors

TNYA vs. ALLO, SLDB, REPL, ANRO, and ZVRA

How does Tenaya Therapeutics compare to Allogene Therapeutics?

Summary

How does Tenaya Therapeutics compare to Solid Biosciences?

Summary

How does Tenaya Therapeutics compare to Replimune Group?

Summary

How does Tenaya Therapeutics compare to Alto Neuroscience?

Summary

How does Tenaya Therapeutics compare to Zevra Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA vs. The Competition

Tenaya Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tenaya Therapeutics (TNYA) Competitors

TNYA vs. ALLO, SLDB, REPL, ANRO, and ZVRA

How does Tenaya Therapeutics compare to Allogene Therapeutics?

Do analysts recommend TNYA or ALLO?

Does the media favor TNYA or ALLO?

Do institutionals & insiders have more ownership in TNYA or ALLO?

Which has more risk & volatility, TNYA or ALLO?

Which has preferable earnings and valuation, TNYA or ALLO?

Is TNYA or ALLO more profitable?

Summary

How does Tenaya Therapeutics compare to Solid Biosciences?

Does the media prefer SLDB or TNYA?

Which has stronger earnings and valuation, SLDB or TNYA?

Do insiders & institutionals hold more shares of SLDB or TNYA?

Do analysts recommend SLDB or TNYA?

Is SLDB or TNYA more profitable?

Which has more risk & volatility, SLDB or TNYA?

Summary

How does Tenaya Therapeutics compare to Replimune Group?

Is TNYA or REPL more profitable?

Does the media favor TNYA or REPL?

Which has more risk and volatility, TNYA or REPL?

Which has stronger earnings & valuation, TNYA or REPL?

Do insiders & institutionals believe in TNYA or REPL?

Do analysts rate TNYA or REPL?

Summary

How does Tenaya Therapeutics compare to Alto Neuroscience?

Does the media favor ANRO or TNYA?

Do analysts prefer ANRO or TNYA?

Which has preferable valuation & earnings, ANRO or TNYA?

Do institutionals and insiders hold more shares of ANRO or TNYA?

Which has more risk & volatility, ANRO or TNYA?

Is ANRO or TNYA more profitable?

Summary

How does Tenaya Therapeutics compare to Zevra Therapeutics?

Is ZVRA or TNYA more profitable?

Which has more risk & volatility, ZVRA or TNYA?

Do insiders & institutionals believe in ZVRA or TNYA?

Which has better earnings and valuation, ZVRA or TNYA?

Does the media favor ZVRA or TNYA?

Do analysts recommend ZVRA or TNYA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TNYA vs. The Competition

Tenaya Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools